Artigos relacionados

Garetosmab (Pasatru)

Monoclonal antibody marketed as Pasatru by Regeneron; reported to reduce new abnormal bone formation by 90 percent in F.O.P.

• Novos Tratamentos Oferecem Esperança para Pacientes com o Distúrbio Ósseo Descontrolado F.O.P.